Company News for July 13, 2026

WD-40 shares jumped 10.7% after Q3 2026 EPS of $2.33 beat the Zacks Consensus of $1.58. Delta Air Lines shares fell 1.8% as Q2 2026 revenue of $17.67B missed consensus by 0.53%, while Nurix Therapeutics dropped 6.6% on a 36.76% revenue miss ($9.04M vs. consensus). Freeport-McMoRan gained 1.6% alongside strength in materials stocks, keeping the overall tape reaction mixed across earnings results.

Analysis

This is mostly a dispersion tape, not a macro read-through. The key tell is that the market rewarded proof of margin/operating leverage in a branded consumer name while punishing revenue misses where top-line is the real product: airlines and early-stage biotech. For WDFC, the durable signal is less about one quarter’s EPS and more about whether pricing plus cost discipline can keep gross margin above prior-cycle levels; if yes, the stock can re-rate modestly, but the move is vulnerable if next quarter shows only accounting leverage rather than true demand acceleration.

DAL’s miss matters because airlines are now in a regime where small revenue shortfalls flow almost entirely to earnings revisions; the first-order move is modest, but the second-order risk is analyst downgrades to unit revenue assumptions across the group over the next 1-3 months. For NRIX, a revenue gap this size is more damaging than the stock reaction suggests: in biotech, weak monetization often triggers a financing discount, delayed partnership value, and higher probability of dilution within 6-18 months unless management can show a credible cash runway extension.

FCX is the cleanest macro beta here, but the stock’s limited move implies the market is still treating materials as a trading basket rather than a sustained China-demand call. Contrarian view: the crowd may be underestimating how fast a few weak airline/biotech prints can compress forward multiples, while overestimating the durability of single-quarter beats in defensive consumer names. Falsifiers: WDFC needs follow-through on organic sales, DAL needs stable PRASM/guidance, NRIX needs a visible partner/cash runway inflection, and FCX needs copper to hold recent highs rather than just broad sector rotation.

Key Decisions for Investors

• Short NRIX vs long XBI for 1-3 months on any post-earnings bounce; thesis is execution + financing risk, with upside limited unless revenue re-accelerates materially. Stop if management extends cash runway or adds a material partnering catalyst.
• Buy FCX 1-3 month call spreads on weakness, or wait for confirmation from copper inventory/China stimulus data before entering; this is a defined-risk way to express a materials re-rating. Fails if copper gives back recent highs or China macro data rolls over.